Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Org Biomol Chem ; 19(8): 1854-1859, 2021 03 04.
Article in English | MEDLINE | ID: mdl-33565553

ABSTRACT

A method for the microwave-assisted copper-mediated oxidative coupling reaction of different aldehydes and quinazolines/benzimidazoles has been developed for the synthesis of fused-polycyclic systems via new C-N bond formation. The current methodology involves the use of environmentally benign NH4OAc as the amine source in the presence of 2-propanol as the solvent. This novel tandem reaction approach offers a rapid and straightforward access to complex fused quinazoline derivatives in an efficient manner.

2.
J Mol Model ; 25(3): 65, 2019 Feb 14.
Article in English | MEDLINE | ID: mdl-30762124

ABSTRACT

Soft spot analysis helps evaluate the site of the metabolic lability that impacts the bio-availability of the drug. However, given its laborious and time consuming experimentation, we propose a reliable and cheap in silico strategy. In this context, we hypothesized a mechanistic rationale for metabolism of erlotinib by the CYP3A4 enzyme. The comparison of the 3D conformations of the target CYP class of enzymes using MD simulations with GROMACS helped evaluate its impact on the metabolism. The molecular docking studies using Autodock-Vina ascertained the explicit role of the Fe ion present in the Heme moiety in this process. This mechanism was confirmed with respect to 13 other popular approved FDA kinase inhibitors using ab initio DFT calculations using Gaussian 09 (G09), molecular docking studies with Autodock-Vina, and MD simulations with GROMACS. We then developed a quantitative (Q-Met) metabolic profile of these soft spots in the molecules and demonstrated the lack of a linear relationship between the extent of metabolism and drug efficacy. We thus propose an economic in silico strategy for the early prediction of the lability in kinase inhibitors to help model their bio-availability and activity simultaneously, prior to clinical testing.


Subject(s)
Cytochrome P-450 CYP3A/chemistry , Erlotinib Hydrochloride/pharmacokinetics , Protein Kinase Inhibitors/chemistry , Binding Sites , Biological Availability , Computer Simulation , Cytochrome P-450 CYP3A/metabolism , Drug Design , Erlotinib Hydrochloride/chemistry , Erlotinib Hydrochloride/metabolism , Humans , Models, Molecular , Molecular Conformation , Molecular Docking Simulation , Molecular Dynamics Simulation , Thermodynamics
SELECTION OF CITATIONS
SEARCH DETAIL
...